Increased incidence of heart disease is reported in patients with diabetes. To elucidate a molecular profile of expressed genes during the progression of diabetes, a cDNA array was screened in the hearts of mice treated with streptozotocin (200 mg/kg, i.v.). Among the genes investigated, the plasma type glutathione peroxidase, GPX-3, was predominantly up-regulated in diabetic mice compared with control mice. In northern blot analysis, a significant increase in GPX-3 expression was observed as early as 5 d after the induction of hyperglycemia. On day 21, a nearly three-fold induction was demonstrated. Daily administration of insulin (0.2 U/d, s.c.) for 21 d almost completely abolished the increase in GPX-3 mRNA in streptozotocin-treated mice, suggesting that the expression level of the GPX-3 gene was dependent on insulin and serum glucose. Increased GPX-3 may play a significant role in protecting cardiomyocytes from oxidative stress caused by hyperglycemia.
Cardiovascular complications of diabetes are the leading cause of mortality. Coronary artery disease is well known as a frequent complication in diabetic patients, while impaired ventricular performance without coronary lesion has been reported in experimental diabetic animals as well as in diabetic patients. 1, 2) One of the mechanisms of such functional impairment is the metabolic perturbation of myocytes, 3) including the acceleration of the polyol pathway, an alternate route of glucose metabolism. 4) On the other hand, the alteration of gene expression under hyperglycemia is another factor involved in the pathogenesis of diabetic cardiomyopathy, which may modulate the cellular metabolism, signal transduction and host defense system. Thus, it is of practical significance to elucidate the differences in gene expression between normal and diabetic subjects. So far, however, the gene expression profile in the diabetic heart has not been well documented. This led us to undertake an investigation of the gene expression profile in experimentally induced diabetic mice using a cDNA array technique. We here report a predominant up-regulation of the plasma type glutathione peroxidase, GPX-3, in the streptozotocin-induced diabetic mouse heart. Since oxidative stress is one of the major causes of diabetic complications, 5, 6) up-regulation of the GPX-3 gene may be a counter-regulatory response in cardiac tissue to attenuate oxidative insults under hyperglycemia.
MATERIALS AND METHODS

Materials
Mouse cDNA macroarray membranes containing 588 known genes were products of Clontech (Palo Alto, CA, U.S.A.). Other reagents were of the highest grade available.
Diabetic Animal Model Male 7-week-old BDF-1 mice fed ad libitum were used in this study cDNA Array Analysis Total RNA was extracted from the whole heart using the ISOGEN RNA extraction reagent (Nippon gene Co., Ltd., Tokyo, Japan) according to the manufacturer's protocol. A pool of mRNA from 5 diabetic or non-diabetic control mice was reverse transcribed, and labeled with [ 32 P]-dCTP according to the manufacture's instruction (Clontech). The array membrane was hybridized with [
32 P]-labeled DNA probes, and the difference in the expression level of each gene between diabetic and control mice was quantified using a BAS2000 Bioimage Analyzer (Fuji Film, Tokyo, Japan). The expression level of each gene was normalized by the levels of glyceraldehydes 3-phosphate dehydrogenase (GAPDH) and b-actin placed on the membrane as internal controls.
Northern Blot Analysis A cDNA probe for the mouse GPX-3 was synthesized by reverse transcription-polymerase chain reaction (RT-PCR) using 5Ј-caaacaggagccaggcgagaac-3Ј (sense) and 5Ј-ggatgtcatggatcttcatgggttc-3Ј (antisense) as primers. Twenty micrograms of total RNA were separated by electrophoresis on a 0.8% agarose/formamide gel, and transferred onto a nylon membrane in 20ϫsodium chloride/ sodium citrate (pH 7.0). The membrane was hybridized with [ 32 P]-labeled cDNA probes, and the level of GPX-3 mRNA was quantified based on the level of GAPDH mRNA. Statistical Analysis All values were expressed as means ϮS.E.M. Group comparisons were analyzed by one-way analysis of variance (ANOVA, Kaleida Graph 3.6 version 3.00, Synergy Software). All groups were analyzed simultaneously with Dunnett's test. A difference with pϽ0.05 was considered significant.
RESULTS
cDNA Array Analysis of the Heart Isolated from Diabetic Mice A significant increase in the serum glucose level was observed at 5 d after STZ administration, while a significant decrease in body weight was demonstrated at 21 d after administration (Table 1) . No difference in the heart to body weight ratio was observed during this period. At 21 d after the induction of hyperglycemia, the cDNA array analysis was performed using RNA preparations obtained from diabetic or non-diabetic mouse hearts. As shown in Fig. 1 , several candidate genes of which expression levels appeared to decrease under hyperglycemia were: transferrin receptor protein (p90; CD71), KDR/flk1 vascular endothelial growth factor tyrosine kinase receptor 2 (VEGFR2) and retinoic acid receptor b-2 (b2-RAR). Conversely, candidate genes of which expression levels appeared to increase were: vascular endothelial growth factor receptor 1 (VEGFR1), HSP84, interleukin-6 receptor beta chain, glutathione S-transferase Mu 1, nucleoside diphosphate kinase B, ubiquitin-conjugating enzyme, cathepsin D, cathepsin L and glutathione peroxidase-3 (GPX-3). Among these genes, we focused on an antioxidant enzyme, GPX-3, since augmented oxidative stress is implicated in the pathogenesis of cardiac dysfunction. [7] [8] [9] Increased Expression of the GPX-3 Gene in the Heart under Hyperglycemia To confirm the augmented expression of GPX-3 gene in the diabetic mouse heart, northern blot analyses were carried out using total RNA isolated from STZ-induced diabetic mice. As shown in Fig. 2 , a significant increase in GPX-3 gene expression was observed as early as 5 d after STZ administration. The increased level of the GPX-3 transcript remained up to 3 weeks after the induction of hyperglycemia. A maximal induction of about 3-fold was observed at this time point.
The diabetogenic effects of STZ include liberation of toxic amounts of nitric oxide, NO, leading to the rapid destruction of pancreatic b-cells. 10) To clarify whether the decrease was due to the irrelevant effects of STZ on blood insulin or glucose level, we examined the effect of insulin administration on the GPX-3 gene expression. Insulin treatment significantly restored the serum glucose level and body weight of STZ-treated mice ( Table 2 ). The increase in GPX-3 expression in the heart of diabetic mice was almost completely abolished by the administration of insulin (Fig. 3) , while insulin itself did not affect GPX-3 expression in the control 
Fig. 2. Northern Blot Analysis of GPX-3 Gene Expression in Diabetic Mouse Heart
Total RNA (20 mg) extracted from the whole heart of hyperglycemic (STZ) or euglycemic (control) mice was subjected to northern blot analyses at indicated times after STZ injection. The membranes were stripped and rehybridized for GAPDH. The GPX-3/GAPDH ratio is expressed relative to that of the non-diabetic control. The values represent meansϮS.E.M. (nϭ4-6). * pϽ0.05 vs. control. non-diabetic mice. These results suggested that the expression of the GPX-3 gene was dependent on the deficiency of insulin and increased blood glucose level.
DISCUSSION
The alteration of gene expression by hyperglycemia results in the modulation of the cellular metabolism, signal transduction and host defense system. In this study, we identified the increased expression of the GPX-3 gene in the heart of STZ-induced diabetic mice using a cDNA array. The administration of insulin to STZ-induced diabetic mice completely abolished the GPX-3 induction while insulin alone neither induced hyperglycemia nor affected GPX-3 expression in the control non-diabetic mice. These results suggest that hyperglycemia plays a key role in the up-regulation of GPX-3 gene expression. An increase in GPX-3 expression was demonstrated in a type 1 diabetic model induced by STZ administration. The result raised the intriguing question whether GPX-3 expression is also up-regulated in type 2 diabetic subjects. As the increase in GPX-3 was one of the major events in the heart under hyperglycemia, GPX-3 gene expression may be induced in a similar fashion in type 2 diabetic models as well. It, however, needs to be confirmed by further studies.
The family of glutathione peroxidases, GPXs, comprises four distinct mammalian selenoproteins. GPXs are enzymes that catalyze the reduction of hydrogen peroxide and alkyl hydroperoxide at the expense of glutathione. GPX-3 has been categorized as the plasma type GPX that is secreted into the surrounding extracellular environment from a number of organs including the kidney, liver, skeletal muscle, pancreas, brain, lung and heart.
11) It has been reported that hyperglycemia increases cellular oxidative stress, which is known to be one of the mechanisms involved in the development of diabetic complications. 5, 6) In STZ-induced diabetic mice, the level of urine oxidative markers, 8-hydroxydeoxyguanosine and 8-isoprostane, were shown to be elevated. 12) Furthermore, increasing evidence suggests that oxidative stress also plays a critical role in the pathogenesis of heart failure. [7] [8] [9] It can therefore be postulated that augmented oxidative stress under hyperglycemia may accelerate the development of heart failure in diabetic patients.
The promoter region of the human GPX-3 gene contains an antioxidant response element (ARE) and metal response element (MRE). 13) These two elements are known to be responsive to oxidative substances such as hydrogen peroxide and t-butyl hydroperoxide.
14-16) Accordingly, cellular oxidative stress under hyperglycemia may up-regulate the expression of the GPX-3 gene through these response elements.
In the diabetic heart, GPX-3 may serve as a direct scavenger of reactive peroxides. It is reported that the level of 4-hydroxynonenal (4-HNE), a metabolite of lipid peroxides, is elevated in the STZ-induced diabetic mouse heart. 17) As 4-HNE is known to modify proteins to disturb cellular function, 18) increased GPX-3 may protect cells from protein modifications by lipid peroxides. GPX-3 secreted from cells into the blood may also function as a barrier for hydroperoxide transfer through the cell membrane. Increased GPX-3 may further affect the host defense system by regulating proinflammatory lipid mediators originated from lipoxygenases. One of the unique properties of GPX-3 is that, in place of GSH, it can utilize thioredoxin and glutaredoxin as reducing thiol substrates. 19) Since the level of thioredoxin in diabetic patients is reported to increase, 20) GPX-3 may scavenge reactive peroxides cooperating with the increased thioredoxin under these conditions.
Taken together, the present study provides the first evidence for the up-regulation of GPX-3 in the cardiac tissue of diabetic mice. As the levels of other antioxidative enzymes such as the cellular glutathione peroxidase (GPX-1) and superoxide dismutase-1 were unchanged in STZ-induced diabetic mice, 12) GPX-3 appears to be the major antioxidative enzyme that takes part in the cellular defense response against oxidative stress under hyperglycemia. 
